A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) (NCT04853576)

🧪 Interventions in This Study

• EDIT-301 (GENETIC)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• UCSF Benioff Children's Hospital — Oakland, California
• Children's Hospital Colorado — Aurora, Colorado
• Smilow Cancer Hospital — New Haven, Connecticut
• Johns Hopkins All Children's Hospital — St. Petersburg, Florida
• Children's Healthcare of Atlanta — Atlanta, Georgia
• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
• University of Mississippi Medical Center — Jackson, Mississippi
• Hackensack University Medical Center — Hackensack, New Jersey
• Columbia University Medical Center - Department of Pediatrics — New York, New York
• Columbia University Medical Center — New York, New York
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Atrium Health — Charlotte, North Carolina
• University Hospitals Rainbow Babies & Children's Hospital — Cleveland, Ohio
• Cleveland Clinic — Cleveland, Ohio
• Nationwide Children's Hospital — Columbus, Ohio
• The James Cancer Hospital — Columbus, Ohio
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
• Medical University of South Carolina — Charleston, South Carolina
• Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers — Nashville, Tennessee
• Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
• Cook Children's — Fort Worth, Texas
• Ottawa Hospital Research Institute — Ottawa, Ontario
• Princess Margaret Cancer Centre — Toronto, Ontario
• Centre Hospitalier Universitaire Sainte-Justine — Montreal, Quebec

📞 Contact the Study Coordinator

Phone: (877) 827-3222

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Sickle Cell Disease

• Kidney Function in Sickle Cell Anemia — Chapel Hill, North Carolina
• BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease — Birmingham, Alabama
• Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease — Bethesda, Maryland
• Acupressure in Patients With Sickle Cell Disease — Irvine, California
• Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) — Chicago, Illinois
• Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) — Charlotte, North Carolina

Explore by condition: All Sickle Cell Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.